10-Q: Foghorn Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Quarterly Report
Foghorn Therapeutics reported a net loss of $19.1 million for the third quarter of 2024, with collaboration revenue decreasing due to the termination of the Merck agreement, offset by increased revenue from the Lilly collaboration.
Summary
- Foghorn Therapeutics reported a net loss of $19.1 million for the third quarter of 2024, compared to a net loss of $14.3 million for the same period in 2023.
- The company's collaboration revenue decreased to $7.8 million in Q3 2024 from $17.5 million in Q3 2023, primarily due to the termination of the Merck collaboration agreement.
- This decrease was partially offset by an increase in revenue from the Eli Lilly collaboration, which reached $7.8 million in Q3 2024.
- Research and development expenses decreased slightly to $24.7 million in Q3 2024 from $26.3 million in Q3 2023.
- General and administrative expenses also decreased to $7.0 million in Q3 2024 from $8.3 million in Q3 2023.
- The company's cash, cash equivalents, and marketable securities totaled $267.4 million as of September 30, 2024.
- Foghorn expects its current cash position to fund operations for at least the next 12 months.
- The company is conducting a Phase 1 dose escalation study of FHD-286 in AML patients and a Phase 1 dose escalation study of FHD-909 for SMARCA4 mutated cancers with Lilly.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company has a strong cash position and is making progress with its clinical programs, the increased net loss and decreased collaboration revenue are concerning. The need for future capital raises also adds uncertainty.
Positives
- The company's cash position is expected to fund operations for at least the next 12 months.
- The Phase 1 dose escalation study of FHD-909 has commenced with the first patient dosed in October 2024.
- The company has made progress in its collaboration with Eli Lilly and Company.
- The company has a strong cash position of $267.4 million.
Negatives
- The company reported a net loss of $19.1 million for the third quarter of 2024.
- Collaboration revenue decreased significantly due to the termination of the Merck agreement.
- The company recognized a non-cash impairment charge of $2.4 million related to a sublease of office space.
- The company has an accumulated deficit of $538.7 million.
Risks
- The company is subject to risks similar to other clinical-stage biopharmaceutical companies, including dependence on key individuals, competition, and the need for additional financing.
- There is no assurance that the company's research and development will be successful or that any products developed will be commercially viable.
- The company may not be able to obtain financing on acceptable terms, or at all.
- The company's operating losses are expected to continue in the foreseeable future.
- The company's ability to generate product revenue depends on the successful development and commercialization of its product candidates.
- The company is exposed to risks related to geopolitical instability and armed conflict.
Future Outlook
The company expects to continue to incur significant expenses and increasing operating losses for at least the next several years. They anticipate that their cash, cash equivalents and marketable securities will be sufficient to fund their operating expenses and capital expenditure requirements for at least 12 months. The company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements to continue to fund its operations.
Management Comments
- The company is focused on advancing its clinical programs and platform.
- The company believes its current pipeline has the potential to help more than 500,000 cancer patients.
- The company is taking a small molecule modality agnostic approach to drugging targets.
- The company is a biology first company, focusing on the underlying genetics and biology of a disease relevant target.
Industry Context
The company is operating in the competitive biopharmaceutical industry, focusing on novel therapeutics targeting the chromatin regulatory system. This approach is unique and could lead to new classes of precision medicines. The company's collaboration with Eli Lilly is a significant development, indicating industry interest in their platform and approach.
Comparison to Industry Standards
- Foghorn's financial results are typical for a clinical-stage biopharmaceutical company, with significant operating losses and reliance on collaboration revenue and capital raises.
- The company's research and development expenses are in line with other companies in the sector that are advancing multiple clinical programs.
- The company's cash position is relatively strong compared to other companies of similar size, providing a runway for continued operations.
- The collaboration with Eli Lilly is a significant partnership, similar to other biotech companies that partner with larger pharmaceutical companies to advance their programs.
- The company's focus on the chromatin regulatory system is a novel approach, differentiating it from other companies that are targeting more traditional pathways.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Business Officer | NA | Anna Rivkin | September 1, 2024 | New hire |
| Treasurer and interim Chief Financial Officer | Stephen J. DiPalma | NA | April 16, 2024 | Interim role ended |
Related Party Transactions
- The company has a consulting agreement with a scientific founder who is also a shareholder.
- The company has a collaboration agreement and stock purchase agreement with Eli Lilly and Company, making them a 5% or greater shareholder.
- The company had an agreement with Danforth Advisors, LLC for strategic and financial consulting services, and a managing director at Danforth served as interim CFO.
Stakeholder Impact
- Shareholders are impacted by the company's financial performance and the need for additional capital raises.
- Employees are impacted by the company's financial performance and any changes in headcount.
- Customers (potential patients) are impacted by the company's ability to develop and commercialize new therapies.
- Suppliers and creditors are impacted by the company's financial stability and ability to meet its obligations.
- The company's collaboration with Eli Lilly impacts the development and commercialization of its product candidates.
Next Steps
- Continue the Phase 1 dose escalation study of FHD-286 in AML patients.
- Continue the Phase 1 dose escalation study of FHD-909 for SMARCA4 mutated cancers with Lilly.
- Advance other preclinical programs and identify additional product candidates.
- Seek additional funding through various sources.
- Continue to develop and expand the capabilities of the Gene Traffic Control platform.
Key Dates
| Date | Description |
|---|---|
| October 2015 | Foghorn Therapeutics Inc. was founded as a Delaware corporation. |
| July 2020 | The company entered into a collaboration agreement with Merck. |
| October 21, 2020 | The company's board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (ESPP). |
| December 2021 | The company entered into a collaboration agreement with Eli Lilly and Company. |
| January 2022 | Foghorn received an upfront payment of $300.0 million from Lilly. |
| August 9, 2023 | Merck notified Foghorn of the termination of their collaboration agreement. |
| November 7, 2023 | The Merck Collaboration Agreement was terminated. |
| January 1, 2024 | The share pool under the 2020 Equity Incentive Plan was increased by 1,691,281 shares. |
| January 1, 2024 | The number of shares reserved for issuance under the ESPP was increased by 422,820 shares to 1,566,120 shares. |
| January 16, 2024 | Stephen J. DiPalma was appointed as Treasurer and interim Chief Financial Officer. |
| April 16, 2024 | Stephen J. DiPalma's term as Treasurer and interim Chief Financial Officer ended. |
| May 2024 | The company entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. |
| May 10, 2024 | The company entered into a sublease agreement for office space. |
| May 22, 2024 | The public offering of common stock and pre-funded warrants closed, resulting in net proceeds of $102.8 million. |
| July 1, 2024 | The sublease agreement commenced. |
| July 18, 2024 | Anna Rivkin's employment agreement as Chief Business Officer was signed. |
| September 1, 2024 | Anticipated start date for Anna Rivkin as Chief Business Officer. |
| September 30, 2024 | End of the reporting period for the third quarter of 2024. |
| October 2024 | The first patient was dosed in the Phase 1 dose escalation study of FHD-909. |
| October 28, 2024 | The company had 55,593,131 shares of common stock outstanding. |
| November 4, 2024 | The date of the filing of the Quarterly Report on Form 10-Q. |
Keywords
biopharmaceutical, oncology, chromatin regulatory system, FHD-286, FHD-909, Eli Lilly, clinical trials, Gene Traffic Control, SMARCA2, SMARCA4, AML, research and development, collaboration, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.